G47Δ-angio

G47Δ-angio is a third-generation oncolytic herpes simplex virus type 1 (oHSV-1) engineered to express human angiostatin. It is built upon the G47Δ backbone, which features three specific mutations: deletions in the γ34.5 and ICP47 genes, and an inactivation of the ICP6 gene. These modifications enhance the virus's safety profile and its ability to selectively replicate within and lyse tumor cells while stimulating an anti-tumor immune response. By incorporating the gene for angiostatin, a potent endogenous inhibitor of angiogenesis, G47Δ-angio combines direct viral oncolysis with the inhibition of tumor-associated blood vessel growth. This dual-action approach is intended to improve therapeutic efficacy in highly vascularized tumors such as glioblastoma, where it has been studied both as a monotherapy and in combination with other anti-angiogenic agents like bevacizumab.

Other names

G47Δ-angiostatinG47delta-angiostatinG-47delta-angiostatinG 47delta-angiostatin